Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0JP4H
|
||||
| Former ID |
DAP000047
|
||||
| Drug Name |
Bethanidine
|
||||
| Synonyms |
Betanidina; Betanidine; Betanidinum; Betanidole; Bethanid; Esbatal; Regulin; Tenathan; Bethanidine hemisulfate; Bethanidinesulfate; BW 467C60; BW467C60; Betanidina [INN-Spanish]; Betanidine [INN:BAN]; Betanidinum [INN-Latin]; Esbatal (TN); Regulin (TN); Tenathan (TN); Bethanidine Sulfate (2:1); Ulfate (2:1); BW-467-C-60;Bethanidine Sulfate (2:1) (USAN); Bethanidine, Sulfate (2:1); Guanidine, 1-benzyl-2,3-dimethyl-(8CI); Guanidine, 1-benzyl-2,3-dimethyl-, s; N-Benzyl-N',N''-dimethylguanidine sulfate; N,N'-dimethyl-N''-(phenylmethyl)-guanidine; Sulfuric acid compound with N''-benzyl-N,N'-dimethylguanidine (1:1); Guanidine, N, N'-dimethyl-N''-(phenylmethyl)-, sulfate (2:1); 1,2-dimethyl-3-(phenylmethyl)guanidine; 1-BENZYL-2,3-DIMETHYLGUANIDINE; 1-Benzyl-2,3-dimethylguanidine sulfate; 1-Benzyl-2,3-dimethylguanidine sulfate (1:1/2); 1-Benzyl-2,3-dimethylguanidinium sulfate; 2-Benzyl-1,3-dimethylguanidine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Hypertension; Heart arrhythmia [ICD9: 401; ICD10:I10-I16, I47-I49] | Approved | [1], [2], [3] | ||
| Therapeutic Class |
Antihypertensive Agents
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C10H15N3
|
||||
| InChI |
InChI=1S/C10H15N3/c1-11-10(12-2)13-8-9-6-4-3-5-7-9/h3-7H,8H2,1-2H3,(H2,11,12,13)
|
||||
| InChIKey |
NIVZHWNOUVJHKV-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 2181-76-2
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
794603, 4422028, 4858569, 10527186, 10684853, 15017208, 24434881, 29221536, 46507605, 48415637, 49974299, 49974300, 57321284, 76033440, 85209720, 103098581, 104300389, 117516657, 124968877, 126407344, 128708764, 132511343, 134222405, 134972441, 137127281, 137142853, 160963565, 164845970, 172912991, 179150629, 179225536, 184547122, 198944926, 223365953, 226420897, 249933805
|
||||
| ChEBI ID |
ChEBI:3079
|
||||
| SuperDrug ATC ID |
C02CC01
|
||||
| SuperDrug CAS ID |
cas=000055732
|
||||
| Target and Pathway | |||||
| Target(s) | Beta-1 adrenergic receptor | Target Info | Antagonist | [4] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| cGMP-PKG signaling pathway | |||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Endocytosis | |||||
| Adrenergic signaling in cardiomyocytes | |||||
| Gap junction | |||||
| Salivary secretion | |||||
| Dilated cardiomyopathy | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Beta1 adrenergic receptor signaling pathway | |||||
| PathWhiz Pathway | Muscle/Heart Contraction | ||||
| Reactome | Adrenoceptors | ||||
| G alpha (s) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| Calcium Regulation in the Cardiac Cell | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Endothelin Pathways | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Antiarrhythmic, antifibrillatory, and hemodynamic actions of bethanidine sulfate: an orally effective analog of bretylium for suppression of ventricular tachyarrhythmias. Am J Cardiol. 1982 Oct;50(4):728-34. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7618). | ||||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 4 | Withdrawal syndromes and the cessation of antihypertensive therapy. Arch Intern Med. 1981 Aug;141(9):1125-7. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.